Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 1/20 | 0.52 |
| ▸ | CCND1 | P24385 | 1/20 | 0.52 |
| ▸ | CCND2 | P30279 | 1/20 | 0.52 |
| ▸ | CCND3 | P30281 | 1/20 | 0.52 |
| ▸ | IGF1R | P08069 | 1/20 | 0.48 |
| ▸ | JAK3 | P52333 | 13/20 | 0.48 |
| ▸ | PTK2 | Q05397 | 13/20 | 0.48 |
| ▸ | JAK2 | O60674 | 12/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.45 |
| ▸ | MTOR | P42345 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3337716 | 0.91 | CDK4 (0.64) | CDK4CCND1CCND2CCND3 | |
| SCHEMBL3341176 | 0.87 | CDK4 (0.55) | CDK4CCND1CCND2CCND3IGF1R | |
| SCHEMBL3338442 | 0.84 | PIK3CA (0.49) | CDK4CCND1CCND2CCND3PIK3CA | |
| Hydrochloric Acid SCHEMBL3345003 | 0.83 | PIK3CA (0.48) | CDK4CCND1CCND2CCND3PIK3CA | |
| SCHEMBL4232772 | 0.79 | CCND3 (0.51) | CDK4CCND1CCND2CCND3IGF1R | |
| SCHEMBL4213976 | 0.79 | CDK4 (0.60) | CDK4CCND1CCND2CCND3 | |
| SCHEMBL3340843 | 0.78 | CDK4 (0.64) | CDK4CCND1CCND2CCND3PIK3CA | |
| SCHEMBL3341919 | 0.78 | CDK4 (0.62) | CDK4CCND1CCND2CCND3 | |
| SCHEMBL3344173 | 0.77 | CDK4 (0.68) | CDK4CCND1CCND2CCND3JAK3 | |
| Hydrochloric Acid SCHEMBL3344416 | 0.77 | CDK4 (0.62) | CDK4CCND1CCND2CCND3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2142543-B1 | PYRIDO [2, 3-D]PYRIMIDIN-7-ONE COMPOUNDS AS INHIBITORS OF PI3K-ALPHA FOR THE TREATMENT OF CANCER | EXELIXIS INC (US) | 2013-05-22 | — | — | EP | disclosed |
| US-20100150827-A1 | PYRIDO [2, 3-D] PYRIMIDIN-7-ONE COMPOUNDS AS INHIBITORS OF P13K-ALPHA FOR THE TREATMENT OF CANCER | EXELIXIS, INC (US) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100150827-A1 | PYRIDO [2, 3-D] PYRIMIDIN-7-ONE COMPOUNDS AS INHIBITORS OF P13K-ALPHA FOR THE TREATMENT OF CANCER | PIK3CA, CDKN1A, PIK3CD | CDK4 47/4885CCND1 141/4885CCND2 225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.